Zoetis: The Pet Spending Thesis Meets Its First Real Challenge

Zoetis Inc. (NYSE: ZTS), the world's leading animal health company, reports first-quarter 2026 earnings before the market opens on Wednesday, May 7, 2026. With the stock trading below all major moving averages and technical signals flashing strong sell warnings, investors will scrutinize whether the company can maintain its streak of consistent earnings beats amid a challenging technical backdrop. The report arrives as analysts project 8.78% year-over-year EPS growth to $1.61, but the stock's 100% sell signal across all timeframes suggests the market has priced in significant headwinds.

Part 1: Earnings Preview

Zoetis develops, manufactures, and markets veterinary medicines, vaccines, diagnostics, and services for companion animals (dogs, cats) and livestock (cattle, swine, poultry, fish). The company serves veterinarians, livestock producers, and pet owners globally, operating as the largest pure-play animal health business following its 2013 spinoff from Pfizer.

Zoetis will report Q1 2026 results on May 7, 2026, with analysts expecting $1.61 per share on revenue of $2.30 billion. The company most recently reported $1.48 EPS for Q4 2025, beating estimates by 5.71%. Compared to the same quarter last year when Zoetis earned $1.48 per share, the consensus forecast represents 8.78% year-over-year growth—a solid acceleration that reflects the company's pricing power and portfolio strength.

Three key themes define this earnings story:

Companion Animal Momentum vs. Livestock Headwinds: Analysts project companion animal revenues of $1.58 billion (up 2.3% year-over-year) while livestock revenues are expected at $680.48 million (up 5.5%). The divergence between these segments will reveal whether Zoetis can sustain growth as pet ownership trends normalize post-pandemic while livestock producers face margin pressures. The companion animal business—representing roughly 70% of total revenue—remains the growth engine, but livestock performance will signal whether the company can maintain balanced portfolio expansion.

International Revenue Acceleration: With international revenues projected at $1.08 billion (up 6.7% year-over-year) versus U.S. revenues of $1.20 billion (up just 1.2%), geographic mix is critical. Analysts expect international companion animal sales of $609.45 million (up 6.4%) and international livestock of $465.47 million (up 7.0%), suggesting emerging markets are driving incremental growth. Any commentary on China demand, European veterinary clinic traffic, or Latin American livestock production will move the stock.

Full-Year Guidance Trajectory: Zoetis set FY 2026 guidance of $7.00–$7.10 EPS on revenue of $9.8–$10.0 billion when it reported Q4 results in February. With analysts now modeling $7.01 for the full year, the company has minimal cushion. Investors will parse Q1 results for signals on whether Zoetis can beat the high end of guidance or if margin pressures and volume softness force a revision. The company's track record of raising guidance mid-year makes this a high-stakes data point.

Leading analysts remain cautiously optimistic. Wall Street commentary emphasizes Zoetis' durable competitive moat in animal health, with its portfolio of patented parasiticides and vaccines providing recurring revenue streams. However, concerns center on veterinary clinic visit trends for companion animals and whether livestock producers will delay purchases amid commodity price volatility. One analyst noted that Zoetis' ability to take price increases without volume erosion will be tested in this environment, making gross margin performance a critical metric to watch.

Part 2: Historical Earnings Performance

Zoetis has established a consistent pattern of beating earnings estimates, with the company exceeding consensus in each of the past four quarters. The beats have been meaningful: +5.71% in Q1 2025, +8.64% in Q2 2025, +4.94% in Q3 2025, and +5.71% again in Q4 2025. This track record demonstrates management's conservative guidance philosophy and the company's ability to outperform even as analysts raise their bars.

The magnitude of beats has remained relatively stable, clustering in the 5–9% range, which suggests operational consistency rather than wildly volatile results. Notably, Q2 2025 delivered the largest surprise at +8.64% ($1.76 actual vs. $1.62 estimate), while Q3 2025 showed the smallest beat at +4.94% ($1.70 vs. $1.62). The fact that Zoetis beat by the same +5.71% margin in both Q1 and Q4 of 2025 indicates a disciplined forecasting process.

Heading into Q1 2026, this history sets a high bar. With analysts projecting $1.61, investors will likely expect another beat—perhaps in the $1.65–$1.68 range based on historical patterns. Any miss or even an in-line result could disappoint a market accustomed to upside surprises, particularly given the stock's current technical weakness.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Zoetis typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price action reveals significant volatility on earnings day, with Day 0 absolute moves averaging 5.68% and intraday ranges averaging 6.29%. The direction has been mixed: the most recent report (February 2026) saw a -2.35% decline despite a beat, while November 2025 delivered a sharp -13.78% drop—the largest move in the dataset. Conversely, August 2024 and May 2024 both produced gains exceeding +5.5%, showing the stock can rally strongly on positive surprises.

Day +1 follow-through has been more muted, averaging 1.66% with a 3.45% range, suggesting most of the price discovery happens immediately. Notably, May 2025 showed a +4.08% Day +1 gain after an initial -5.18% Day 0 decline, indicating the market sometimes reassesses results overnight. The pattern suggests investors should brace for a 5–7% swing on May 7, with direction hinging on whether the company beats estimates and, crucially, on guidance commentary.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 7.78% (±$8.65) through the May 15 expiration, which aligns closely with the 5.68% average historical Day 0 move but sits below the 6.29% average intraday range. This suggests options traders are anticipating typical earnings volatility rather than an outsized reaction, though the 9-day window to expiration captures both the immediate earnings response and any follow-through momentum.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on Zoetis, with the stock carrying an average recommendation of 4.06 (between Hold and Buy). The consensus has improved over the past month from 4.00, signaling incrementally more bullish sentiment heading into earnings. The rating breakdown shows 9 Strong Buys (up from 8 a month ago), 1 Moderate Buy, and 8 Holds, with zero sell ratings—a distribution that reflects confidence in the company's long-term fundamentals even as near-term concerns persist.

The average price target of $149.69 implies 34.6% upside from the current price of $111.22, a substantial gap that suggests analysts believe the recent selloff has created a buying opportunity. Price targets range from a low of $127.00 to a high of $197.00, with the wide spread reflecting differing views on how quickly Zoetis can reaccelerate growth and expand margins. The fact that the high estimate sits 77% above current levels indicates at least one analyst sees transformative potential in the company's pipeline or market position.

The improved sentiment trend is noteworthy given the stock's technical weakness. The uptick in Strong Buy ratings suggests analysts are looking through near-term volatility and focusing on Zoetis' durable competitive advantages: its leading market share in animal health, recurring revenue from parasiticides and vaccines, and exposure to long-term pet humanization trends. However, the presence of 8 Hold ratings (44% of coverage) indicates some caution, likely tied to valuation concerns after the stock's historical premium multiples and questions about whether companion animal visit trends can sustain growth expectations.

Part 4: Technical Picture

The Barchart Technical Opinion delivers an unambiguous message: Zoetis is in a 100% Sell signal across all recent timeframes—current, one week ago, and one month ago. This persistent bearish reading indicates sustained technical deterioration with no signs of stabilization, creating a challenging setup heading into earnings.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates immediate downward pressure with no near-term relief in sight
• Medium-term (100% Sell): Persistent weakness in the intermediate timeframe suggests the decline is more than a temporary pullback
• Long-term (100% Sell): Bearish signal across the longer-term horizon reflects a fundamental shift in trend structure

Trend Characteristics: The combination of Strong strength and Strongest direction signals an entrenched downtrend with powerful momentum, suggesting any earnings-driven rally would face significant technical resistance.

The stock trades at $111.22, positioned below all major moving averages: the 5-day ($113.11), 10-day ($114.68), 20-day ($117.32), 50-day ($118.92), 100-day ($122.05), and 200-day ($131.66). This complete breakdown below key technical levels indicates a loss of support across all timeframes, with the 200-day moving average now serving as overhead resistance 18.4% above current levels.

The descending moving average structure—where shorter-term averages sit below longer-term ones—confirms a classic downtrend formation. The nearest resistance sits at the 5-day moving average just 1.7% above current levels, while the 50-day at $118.92 represents a more significant hurdle 6.9% higher. With the stock trading at its lowest level relative to moving averages in the dataset and all technical signals flashing red, Zoetis faces a technically hostile environment heading into earnings. Any positive surprise would need to be substantial to overcome this bearish setup, while a miss or weak guidance could accelerate the decline toward the $100 psychological level. The options market's 7.78% expected move suggests traders are bracing for volatility, but the technical damage already done means even a beat may struggle to generate sustained upside without a fundamental shift in sentiment.